HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senator wants FDA action on sunscreen ingredient

This article was originally published in The Rose Sheet

Executive Summary

Referencing preclinical data from the National Center for Toxicological Research and the National Toxicology Program that suggest an association between skin cancer and retinyl palmitate, Sen. Charles E. Schumer, D-N.Y., urges FDA to evaluate data and offer consumer guidance. The vitamin A compound is found in 41% of sunscreens, according to the Environmental Working Group, which also called the ingredient's use into question in its recent state-of-the-market sunscreen report (1"The Rose Sheet" May 31, 2010). EWG claims that for nearly a year, research has been available demonstrating that tumors and lesions developed up to 21% more rapidly in rodents coated with a retinyl-palmitate-based cream, versus animals in the non-RT group, when both groups were exposed to UV radiation. With more Americans using sunscreen over the summer months, "if the product they are using is doing more harm than good, they have a right to know," Schumer asserts in June 14 release. He urges FDA to address concerns about retinyl palmitate and to announce a timeline for its long-delayed sunscreen final rule
Advertisement

Related Content

EWG Advises Against Vitamin A Compound, More Than 90% Of Sunscreens
EWG Advises Against Vitamin A Compound, More Than 90% Of Sunscreens
Advertisement
UsernamePublicRestriction

Register

RS017012

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel